GenSight Biologics reports NEJM publication of Phase 1/2 PIONEER trial results for GS030 in advanced retinitis pigmentosa

• GenSight Biologics reported Phase 1/2 PIONEER trial results for optogenetic candidate GS030 in advanced retinitis pigmentosa in NEJM.
• Results were presented via publication in the Oct. 8, 2026 issue, not flagged for a future conference readout.
• Study met its primary safety focus, with mostly mild-to-moderate eye events and no treatment-related systemic safety signal.
• Exploratory testing showed some patients gained measurable light sensitivity, with functional task improvements when using the stimulation goggles.
• Data support continued development, though findings were described as exploratory and not designed to establish efficacy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gensight Biologics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007824030) on October 08, 2026, and is solely responsible for the information contained therein.